Cost	O
-	O
effectiveness	O
analysis	O
of	O
apatinib	B:C2346836
treatment	O
for	O
chemotherapy	O
-	O
refractory	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
.	O

Cost	O
-	O
effectiveness	O
analysis	O
of	O
apatinib	O
treatment	B:C0087111
for	O
chemotherapy	O
-	O
refractory	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
.	O

Cost	O
-	O
effectiveness	O
analysis	O
of	O
apatinib	O
treatment	O
for	O
chemotherapy	B:C3665472
-	O
refractory	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
.	O

Cost	O
-	O
effectiveness	O
analysis	O
of	O
apatinib	O
treatment	O
for	O
chemotherapy	O
-	O
refractory	O
advanced	B:C0699791
gastric	I:C0699791
cancer	I:C0699791
.	O

Apatinib	B:C2346836
,	O
a	O
third	O
-	I:C2986605
line	I:C2986605
or	O
later	O
treatment	O
for	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
)	O
,	O
was	O
shown	O
to	O
improve	O
overall	O
survival	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
phase	O
III	I:C0282461
trial	I:C0282461
.	O

Apatinib	O
,	O
a	O
third	B:C2986605
-	I:C2986605
line	I:C2986605
or	O
later	O
treatment	O
for	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
)	O
,	O
was	O
shown	O
to	O
improve	O
overall	O
survival	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
phase	O
III	I:C0282461
trial	I:C0282461
.	O

Apatinib	O
,	O
a	O
third	O
-	I:C2986605
line	I:C2986605
or	O
later	O
treatment	B:C0087111
for	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
)	O
,	O
was	O
shown	O
to	O
improve	O
overall	O
survival	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
phase	O
III	I:C0282461
trial	I:C0282461
.	O

Apatinib	O
,	O
a	O
third	O
-	I:C2986605
line	I:C2986605
or	O
later	O
treatment	O
for	O
advanced	B:C0699791
gastric	I:C0699791
cancer	I:C0699791
(	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
)	O
,	O
was	O
shown	O
to	O
improve	O
overall	O
survival	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
phase	O
III	I:C0282461
trial	I:C0282461
.	O

Apatinib	O
,	O
a	O
third	O
-	I:C2986605
line	I:C2986605
or	O
later	O
treatment	O
for	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
advanced	B:C0699791
gastric	I:C0699791
cancer	I:C0699791
)	O
,	O
was	O
shown	O
to	O
improve	O
overall	O
survival	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
phase	O
III	I:C0282461
trial	I:C0282461
.	O

Apatinib	O
,	O
a	O
third	O
-	I:C2986605
line	I:C2986605
or	O
later	O
treatment	O
for	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
)	O
,	O
was	O
shown	O
to	O
improve	O
overall	O
survival	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
compared	O
with	O
placebo	B:C0032042
in	O
the	O
phase	O
III	I:C0282461
trial	I:C0282461
.	O

Apatinib	O
,	O
a	O
third	O
-	I:C2986605
line	I:C2986605
or	O
later	O
treatment	O
for	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
)	O
,	O
was	O
shown	O
to	O
improve	O
overall	O
survival	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
phase	B:C0282461
III	I:C0282461
trial	I:C0282461
.	O

Given	O
the	O
modest	O
benefit	O
with	O
high	O
costs	O
,	O
we	O
further	O
evaluated	B:C0220825
the	O
cost	O
-	O
effectiveness	O
of	O
apatinib	O
for	O
patients	O
with	O
chemotherapy	O
-	O
refractory	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
.	O

Given	O
the	O
modest	O
benefit	O
with	O
high	O
costs	O
,	O
we	O
further	O
evaluated	O
the	O
cost	O
-	O
effectiveness	O
of	O
apatinib	B:C2346836
for	O
patients	O
with	O
chemotherapy	O
-	O
refractory	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
.	O

Given	O
the	O
modest	O
benefit	O
with	O
high	O
costs	O
,	O
we	O
further	O
evaluated	O
the	O
cost	O
-	O
effectiveness	O
of	O
apatinib	O
for	O
patients	O
with	O
chemotherapy	B:C3665472
-	O
refractory	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
.	O

Given	O
the	O
modest	O
benefit	O
with	O
high	O
costs	O
,	O
we	O
further	O
evaluated	O
the	O
cost	O
-	O
effectiveness	O
of	O
apatinib	O
for	O
patients	O
with	O
chemotherapy	O
-	O
refractory	O
advanced	B:C0699791
gastric	I:C0699791
cancer	I:C0699791
.	O

A	O
Markov	O
model	O
was	O
developed	O
to	O
simulate	B:C0679083
the	O
disease	O
process	O
of	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
PFS	O
,	O
progressive	O
disease	I:C1335499
,	O
and	O
death	O
)	O
and	O
estimate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
apatinib	O
to	O
placebo	O
.	O

A	O
Markov	O
model	O
was	O
developed	O
to	O
simulate	O
the	O
disease	B:C0012634
process	O
of	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
PFS	O
,	O
progressive	O
disease	I:C1335499
,	O
and	O
death	O
)	O
and	O
estimate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
apatinib	O
to	O
placebo	O
.	O

A	O
Markov	O
model	O
was	O
developed	O
to	O
simulate	O
the	O
disease	O
process	O
of	O
advanced	B:C0699791
gastric	I:C0699791
cancer	I:C0699791
(	O
PFS	O
,	O
progressive	O
disease	I:C1335499
,	O
and	O
death	O
)	O
and	O
estimate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
apatinib	O
to	O
placebo	O
.	O

A	O
Markov	O
model	O
was	O
developed	O
to	O
simulate	O
the	O
disease	O
process	O
of	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
PFS	O
,	O
progressive	B:C1335499
disease	I:C1335499
,	O
and	O
death	O
)	O
and	O
estimate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
apatinib	O
to	O
placebo	O
.	O

A	O
Markov	O
model	O
was	O
developed	O
to	O
simulate	O
the	O
disease	O
process	O
of	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
PFS	O
,	O
progressive	O
disease	I:C1335499
,	O
and	O
death	B:C0011065
)	O
and	O
estimate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
apatinib	O
to	O
placebo	O
.	O

A	O
Markov	O
model	O
was	O
developed	O
to	O
simulate	O
the	O
disease	O
process	O
of	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
PFS	O
,	O
progressive	O
disease	I:C1335499
,	O
and	O
death	O
)	O
and	O
estimate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
apatinib	B:C2346836
to	O
placebo	O
.	O

A	O
Markov	O
model	O
was	O
developed	O
to	O
simulate	O
the	O
disease	O
process	O
of	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
(	O
PFS	O
,	O
progressive	O
disease	I:C1335499
,	O
and	O
death	O
)	O
and	O
estimate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
apatinib	O
to	O
placebo	B:C0032042
.	O

The	O
health	O
outcomes	O
and	O
utility	O
scores	O
were	O
derived	O
from	O
the	O
phase	B:C0282461
III	I:C0282461
trial	I:C0282461
and	O
previously	O
published	O
sources	I:C1704324
,	O
respectively	O
.	O

The	O
health	O
outcomes	O
and	O
utility	O
scores	O
were	O
derived	O
from	O
the	O
phase	O
III	I:C0282461
trial	I:C0282461
and	O
previously	O
published	B:C1704324
sources	I:C1704324
,	O
respectively	O
.	O

Total	O
costs	O
were	O
calculated	O
from	O
the	O
perspective	O
of	O
the	O
Chinese	B:C2348942
health	I:C2348942
-	I:C2348942
care	I:C2348942
payer	I:C2348942
.	O

Sensitivity	O
analysis	B:C0936012
was	O
used	O
to	O
explore	O
model	O
uncertainties	O
.	O

Sensitivity	O
analysis	O
was	O
used	O
to	O
explore	O
model	O
uncertainties	B:C0087130
.	O

Treatment	B:C0087111
with	O
apatinib	O
was	O
estimated	O
to	O
provide	O
an	O
incremental	O
0.09	O
quality	O
-	O
adjusted	O
life	O
years	O
(	O
QALYs	O
)	O
at	O
an	O
incremental	O
cost	O
of	O
$	O
8113.86	O
compared	O
with	O
placebo	O
,	O
which	O
resulted	O
in	O
an	O
ICER	O
of	O
$	O
90,154.00	O
per	O
QALY	O
.	O

Treatment	O
with	O
apatinib	B:C2346836
was	O
estimated	O
to	O
provide	O
an	O
incremental	O
0.09	O
quality	O
-	O
adjusted	O
life	O
years	O
(	O
QALYs	O
)	O
at	O
an	O
incremental	O
cost	O
of	O
$	O
8113.86	O
compared	O
with	O
placebo	O
,	O
which	O
resulted	O
in	O
an	O
ICER	O
of	O
$	O
90,154.00	O
per	O
QALY	O
.	O

Treatment	O
with	O
apatinib	O
was	O
estimated	O
to	O
provide	O
an	O
incremental	O
0.09	O
quality	O
-	O
adjusted	O
life	O
years	O
(	O
QALYs	O
)	O
at	O
an	O
incremental	O
cost	O
of	O
$	O
8113.86	O
compared	O
with	O
placebo	B:C0032042
,	O
which	O
resulted	O
in	O
an	O
ICER	O
of	O
$	O
90,154.00	O
per	O
QALY	O
.	O

Sensitivity	O
analysis	B:C0936012
showed	O
that	O
across	O
the	O
wide	O
variation	O
of	O
parameters	O
,	O
the	O
ICER	O
exceeded	O
the	O
willingness	O
-	O
to	O
-	O
pay	O
threshold	O
of	O
$	O
23,700.00	O
per	O
QALY	O
which	O
was	O
three	O
times	O
the	O
Gross	O
Domestic	O
Product	O
per	O
Capita	O
in	O
China	O
.	O

Sensitivity	O
analysis	O
showed	O
that	O
across	O
the	O
wide	O
variation	O
of	O
parameters	O
,	O
the	O
ICER	O
exceeded	O
the	O
willingness	O
-	O
to	O
-	O
pay	O
threshold	O
of	O
$	O
23,700.00	O
per	O
QALY	O
which	O
was	O
three	O
times	O
the	O
Gross	O
Domestic	O
Product	O
per	O
Capita	O
in	O
China	B:C0008115
.	O

Apatinib	B:C2346836
is	O
not	O
a	O
cost	O
-	O
effective	O
option	O
for	O
patients	O
with	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
who	O
experienced	O
failure	O
of	O
at	O
least	O
two	O
lines	O
chemotherapy	O
in	O
China	O
.	O

Apatinib	O
is	O
not	O
a	O
cost	O
-	O
effective	O
option	O
for	O
patients	O
with	O
advanced	B:C0699791
gastric	I:C0699791
cancer	I:C0699791
who	O
experienced	O
failure	O
of	O
at	O
least	O
two	O
lines	O
chemotherapy	O
in	O
China	O
.	O

Apatinib	O
is	O
not	O
a	O
cost	O
-	O
effective	O
option	O
for	O
patients	O
with	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
who	O
experienced	O
failure	O
of	O
at	O
least	O
two	O
lines	O
chemotherapy	B:C3665472
in	O
China	O
.	O

Apatinib	O
is	O
not	O
a	O
cost	O
-	O
effective	O
option	O
for	O
patients	O
with	O
advanced	O
gastric	I:C0699791
cancer	I:C0699791
who	O
experienced	O
failure	O
of	O
at	O
least	O
two	O
lines	O
chemotherapy	O
in	O
China	B:C0008115
.	O

However	O
,	O
for	O
its	O
positive	O
clinical	O
value	O
and	O
subliminal	O
demand	O
,	O
apatinib	B:C2346836
can	O
provide	O
a	O
new	O
therapeutic	O
option	O
.	O

However	O
,	O
for	O
its	O
positive	O
clinical	O
value	O
and	O
subliminal	O
demand	O
,	O
apatinib	O
can	O
provide	O
a	O
new	O
therapeutic	B:C0087111
option	O
.	O

